CANNABIS NEWZ
The Wire / Regulation
REGULATIONPortugal

Tilray Medical wins EU-GMP in-house testing approval at Portugal facility

Approval streamlines quality control for producer exporting medicinal cannabis from Portugal, as regulatory environment shows mixed signals.

The Cannabis Newz Automated Desk
Machine-written from our data · source: Cannabis Business Times
October 13, 2026 · 7:00 AM ET
Interior dome of a state capitol buildingFILE — statehouse · B.D. Gilfry / CC BY-SA 2.0
Interior dome of a state capitol building — file photo, not the scene of this story.

Tilray Medical has secured approval to conduct in-house EU-GMP testing at its Portugal facility, according to Cannabis Business Times. The authorization permits the company to perform its own quality assurance testing on-site rather than relying solely on external labs, potentially reducing production delays and improving operational efficiency for a major exporter from Portugal's medicinal cannabis sector.

The approval arrives amid a complex regulatory backdrop. Portugal has expanded its medical cannabis export footprint—shipments surpassed 66 tonnes in 2026—yet the country's regulator has faced criticism for processing delays. Recent coverage indicates Infarmed delays on license renewals have cost producers months, while Spain's GMP operators have begun capturing market share as Portugal stumbles. Tilray's in-house testing capability may help the company sidestep some bottlenecks.

Watch whether other Portuguese producers seek similar testing approvals, and whether this move signals confidence in Portugal's regulatory path or a defensive hedge as competing EU producers gain ground.

Original report: Cannabis Business Times ↗
Written by the Cannabis Newz automated newsroom, grounded in the cited news sources, our wire coverage, official license rosters and market filings — every fact is attributed and machine-checked against those sources before publication. Spotted an error? Tell us via your account page.